Stimulants: Therapeutic actions in ADHD

Neuropsychopharmacology

Volumn 31, Issue 11, 2006, Pages 2376-2383

  Arnsten, Amy F T ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Dopamine; Executive function; Guanfacine; Norepinephrine; Prefrontal cortex; Working memory

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 1A ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; AMPHETAMINE; CATECHOL METHYLTRANSFERASE; CATECHOLAMINE; CENTRAL STIMULANT AGENT; DOPAMINE; DOPAMINE 1 RECEPTOR; GUANFACINE; METHYLPHENIDATE; NORADRENALIN; PRAZOSIN;

ATTENTION; ATTENTION DEFICIT DISORDER; BRAIN CORTEX; BRAIN DYSFUNCTION; BRAIN FUNCTION; CATECHOLAMINE RELEASE; DOPAMINE RELEASE; DOPAMINERGIC TRANSMISSION; DRUG DEPENDENCE; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; DYSPHORIA; HUMAN; LOCOMOTION; LOW DRUG DOSE; NEUROIMAGING; NONHUMAN; NORADRENALIN RELEASE; POSTTRAUMATIC STRESS DISORDER; PREFRONTAL CORTEX; PRIORITY JOURNAL; REVIEW; WORKING MEMORY;

ANIMALS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CATECHOLAMINES; CENTRAL NERVOUS SYSTEM STIMULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; METHYLPHENIDATE; PREFRONTAL CORTEX;

EID: 33750215813     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1301164     Document Type: Review

References (109)

1. Anderson SW, Bechara A, Damasio H, Tranel D, Damasio AR (1999). Impairment of social and moral behavior related to early damage in human prefrontal cortex. Nat Neurosci 2: 1032-1037.
2. Arnsten AFT, Cai JX, Goldman-Rakic PS (1988). The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side effects. J Neurosci 8: 4287-4298.
3. Arnsten AFT, Dudley AG (2005). Methylphenidate improves prefrontal cortical cognitive function through a2 adrenoceptor and dopamine D1 receptor actions: relevance to therapeutic effects in Attention Deficit Hyperactivity Disorder. Behav Brain Funct (Biomed Central) 1: 2.
4. Arnsten AFT, Goldman-Rakic PS (1985). Alpha-2 adrenergic mechanisms in prefrontal cortex associated with cognitive decline in aged nonhuman primates. Science 230: 1273-1276.
5. Arnsten AFT, Li B-M (2005). Neurobiology of executive functions: catecholamine influences on prefrontal cortical function. Biol Psychiatry 57: 1377-1384.
6. Arnsten AFT, Ramos B, Birnbaum SB, Taylor JR (2005). Protein kinase A as a therapeutic target for memory disorders: rationale and challenges. Trends Mol Med 11: 121-128.
7. Arnsten AFT, Robbins TW (2002). Neurochemical modulation of prefrontal cortical function in humans and animals. In: Stuss DT, Knight RT (eds). Principles of Frontal Lobe Function. Oxford University Press: New York. pp 51-84.
8. Arnsten AFT, Steere JC, Hunt RD (1996). The contribution of alpha-2 noradrenergic mechanisms to prefrontal cortical cognitive function: potential significance to Attention Deficit Hyperactivity Disorder. Arch Gen Psychiatry 53: 448-455.
9. Aron AR, Dowson JH, Sahakian BJ, Robbins TW (2003). Methylphenidate improves response inhibition in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 54: 1465-1468.
10. Aron AR, Poldrack RA (2005). The cognitive neuroscience of response inhibition: relevance for genetic research in attention-deficit/hyperactivity disorder. Biol Psychiat 57: 1285-1292.
11. Aron AR, Robbins TW, Poldrack RA (2004). Inhibition and the right inferior frontal cortex. Trends Cogn Sci 8: 170-177.
12. Avery RA, Franowicz JS, Studholme C, van Dyck CH, Arnsten AFT (2000). The alpha-2A-adenoceptor agonist, guanfacine, increases regional cerebral blood flow in dorsolateral prefrontal cortex of monkeys performing a spatial working memory task. Neuropsychopharmacology 23: 240-249.
13. Barkley RA (1997). ADHD and the Nature of Self-Control. Guilford Press: New York.
14. Bartus RT, Levere TE (1977). Frontal decortication in rhesus monkeys: a test of the interference hypothesis. Brain Res 119: 233-248.
15. Bedard AC, Ickowicz A, Logan GD, Hogg-Johnson S, Schachar R, Tannock R (2003). Selective inhibition in children with attention-deficit hyperactivity disorder off and on stimulant medication. J Abnorm Child Psychol 31: 315-327.
16. Bellgrove MA, Hawi Z, Gill M, Robertson IH (2006). The cognitive genetics of attention deficit hyperactivity disorder (ADHD): sustained attention as a candidate phenotype. Cortex (in press).
17. Bellgrove MA, Hawi Z, Lowe N, Kirley A, Robertson IH, Gill M (2005). DRD4 gene variants and sustained attention in attention deficit hyperactivity disorder (ADHD): effects of associated alleles at the VNTR and -521 SNP. Am J Med Genet B Neuropsychiat Genet 136: 81-86.
18. Berridge CW, Devilbiss DM, Andrzejewski ME, Arnsten AFT, Kelley AE, Schmeichel B et al (2006). Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function. Biol Psychiatry [Epub ahead of print].
19. Biederman J, Mick E, Faraone SV, Spencer T, Wilens TE, Wozniak J (2000). Pediatric mania: a developmental subtype of bipolar disorder? Biol Psychiatry 48: 458-466.
20. Birnbaum SB, Yuan P, Bloom A, Davis D, Gobeske K, Sweatt D et al (2004). Protein kinase C overactivity impairs prefrontal cortical regulation of working memory. Science 306: 882-884.
21. Birnbaum SG, Gobeske KT, Auerbach J, Taylor JR, Arnsten AFT (1999). A role for norepinephrine in stress-induced cognitive deficits: alpha-1-adrenoceptor mediation in prefrontal cortex. Biol Psychiatry 46: 1266-1274.
22. Boonstra AM, Oosterlaan J, Sergeant JA, Buitelaar JK (2005). Executive functioning in adult ADHD: a meta-analytic review. Psychol Med 35: 1097-1108.
23. Bush G, Valera EM, Seidman LJ (2005). Functional neuroimaging of attention-deficit/hyperactivity disorder: a review and suggested future directions. Biol Psychiatry 57: 1273-1284.
24. Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heiligenstein JH et al (2002). Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 27: 699-711.
25. Cai JX, Ma Y, Xu L, Hu X (1993). Reserpine impairs spatial working memory performance in monkeys: reversal by the alpha-2 adrenergic agonist clonidine. Brain Res 614: 191-196.
26. Casey BJ, Castellanos FX, Giedd JN, Marsh WL, Hamburger SD, Schubert AB et al (1997). Implication of right frontostriatal circuitry in response inhibition and attention-deficit/hyperactivity disorder. J Am Acad Child Adolescent Psychiatry 36: 374-383.
27. Castellanos FX, Giedd JN, Marsh WL, Hamburger SD, Vaituzis AC, Dickstein DP et al (1996). Quantitative brain magnetic resonance imaging in attention deficit/hyperactivity disorder. Arch Gen Psychiatry 53: 607-616.
28. Castellanos FX, Lee PP, Sharp W, Jeffries NO, Greenstein DK, Clasen LS et al (2002). Developmental trajectories of brain volume abnormalities in children and adolescents with attention-deficit/hyperactivity disorder. JAMA 288: 1740-1748.
29. Dias R, Roberts A, Robbins TW (1996). Dissociation in prefrontal cortex of affective and attentional shifts. Nature 380: 69-72.
30. Durston S, Fossella JA, Casey BJ, Hulshoff Pol HE, Galvan A, Schnack HG et al (2005). Differential effects of DRD4 and DAT1 genotype on fronto-striatal gray matter volumes in a sample of subjects with attention deficit hyperactivity disorder, their unaffected siblings, and controls. Mol Psychiatry 10: 678-685.
31. Elliott R, Sahakian BJ, Matthews K, Bannerjea A, Rimmer J, Robbins TW (1997). Effects of methylphenidate on spatial working memory and planning in healthy young adults. Psychopharmacology 131: 196-206.
32. Faraone SV, Perlis RH, Doyle AE, Smoller JW, Goralnick JJ, Holmgren MA et al (2005). Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry 57: 1313-1323.
33. Filipek PA, Semrud-Clikeman M, Steingard RJ, Renshaw PF, Kennedy DN, Biederman J (1997). Volumetric MRI analysis comparing subjects having attention-deficit hyperactivity disorder with normal controls. Neurology 48: 589-601.
34. Franowicz JCS, Arnsten AFT (1998). The alpha-2A noradrenergic agonist, guanfacine, improves delayed response performance in young adult rhesus monkeys. Psychopharmacology 136: 8-14.
35. Franowicz JS, Kessler L, Dailey-Borja CM, Kobilka BK, Limbird LE, Arnsten AFT (2002). Mutation of the alpha2A-adrenoceptor impairs working memory performance and annuls cognitive enhancement by guanfacine. J Neurosci 22: 8771-8777.
36. French GM (1959). Locomotor effects of regional ablation of frontal cortex in rhesus monkeys. J Comp Physiol Psychol 52: 18-24.
37. Funahashi S, Chafee MV, Goldman-Rakic PS (1993). Prefrontal neuronal activity in rhesus monkeys performing a delayed anti-saccade task. Nature 365: 753-756.
38. Giedd JN, Blumenthal J, Molloy E, Castellanos FX (2001). Brain imaging of attention deficit/hyperactivity disorder. Ann NY Acad Sci 931: 33-49.
39. Godefroy O, Rousseaux M (1996). Divided and focused attention in patients with lesion of the prefrontal cortex. Brain Cognition 30: 155-174.
40. Goldman-Rakic PS (1995). Cellular basis of working memory. Neuron 14: 477-485.
41. Granon S, Passetti F, Thomas KL, Dalley JW, Everitt BJ, Robbins TW (2000). Enhanced and impaired attentional performance after infusion of D1 dopaminergic receptor agents into rat prefrontal cortex. J Neurosci 20: 1208-1215.
42. Gross CG (1963). Locomotor activity following lateral frontal lesions in rhesus monkeys. J Comp Physiol Psychol 56: 232-236.
43. Gross CG, Weiskrantz L (1964). Some changes in behavior produced by lateral frontal lesions in the macaque. In: Warren JM, Akert K (eds). The Frontal Granular Cortex and Behavior. McGraw-Hill Book Co: New York. pp 74-101.
44. Hechtman L, Greenfield B (2003). Long-term use of stimulants in children with attention deficit hyperactivity disorder: safety, efficacy, and long-term outcome. Paediatr Drugs 5: 787-794.
45. Hill DE, Yeo RA, Campbell RA, Hart B, Vigil J, Brooks W (2003). Magnetic resonance imaging correlates of attention-deficit/hyperactivity disorder in children. Neuropsychology 17: 496-506.
46. Itami S, Uno H (2002). Orbitofrontal cortex dysfunction in attention-deficit hyperactivity disorder revealed by reversal and extinction tasks. NeuroReport 13: 2453-2457.
47. Jakala P, Riekkinen M, Sirvio J, Koivisto E, Kejonen K, Vanhanen M et al (1999). Guanfacine, but not clonidine, improves planning and working memory performance in humans. Neuropsychopharmacology 20: 460-470.
48. Kates WR, Frederikse M, Mostofsky SH, Folley BS, Cooper K, Mazur-Hopkins P et al (2002). MRI parcellation of the frontal lobe in boys with attention deficit hyperactivity disorder or Tourette syndrome. Psychiatry Res 116: 63-81.
49. Katusic SK, Barbaresi WJ, Colligan RC, Weaver AL, Leibson CL, Jacobsen SJ (2005). Psychostimulant treatment and risk for substance abuse among young adults with a history of attention-deficit/hyperactivity disorder: a population-based, birth cohort study. J Child Adolesc Psychopharmacol 15: 764-776.
50. Kennard MA, Spencer S, Fountain G (1941). Hyperactivity in monkeys following lesions of the frontal lobes. J Neurophysiol 4: 512-524.
51. Kimberg DY, D'Esposito M, Farah MJ (1997). Effects of bromocriptine on human subjects depend on working memory capacity. NeuroReport 8: 3581-3585.
52. Knight RT, Scabini D, Woods DL (1989). Prefrontal cortex gating of auditory transmission in humans. Brain Res 504: 338-342.
53. Konishi S, Nakajima K, Uchida I, Kikyo H, Kameyama M, Miyashita Y (1999). Common inhibitory mechanism in human inferior prefrontal cortex revealed by event-related functional MRI. Brain 122: 981-991.
54. Kuczenski R, Segal DS (1997). Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: comparison with amphetamine. J Neurochem 68: 2032-2037.
55. Kuczenski R, Segal DS (2002). Exposure of adolescent rats to oral methylphenidate: preferential effects on extracellular norepinephrine and absence of sensitization and cross-sensitization to methamphetamine. J Neurosci 22: 7264-7271.
56. Kuczenski R, Segal DS (2005). Stimulant actions in rodents: implications for attention-deficit/hyperactivity disorder treatment and potential substance abuse. Biol Psychiatry 57: 1391-1396.
57. Larsen JK, Divac I (1978). Selective ablations within the prefrontal cortex of the rat and performance of delayed alternation. Physiol Psychol 6: 15-17.
58. Li B-M, Mao Z-M, Wang M, Mei Z-T (1999). Alpha-2 adrenergic modulation of prefrontal cortical neuronal activity related to spatial working memory in monkeys. Neuropsychopharmacology 21: 601-610.
59. Li B-M, Mei Z-T (1994). Delayed response deficit induced by local injection of the alpha-2 adrenergic antagonist yohimbine into the dorsolateral prefrontal cortex in young adult monkeys. Behav Neural Biol 62: 134-139.
60. Ma C-L, Arnsten AFT, Li B-M (2005). Locomotor hyperactivity induced by blockade of prefrontal cortical alpha-2-adrenoceptors in monkeys. Biol Psychiatry 57: 192-195.
61. Ma C-L, Qi X-L, Peng J-Y, Li B-M (2003). Selective deficit in no-go performance induced by blockade of prefrontal cortical alpha2-adrenoceptors in monkeys. NeuroReport 14: 1013-1016.
62. Malmo RB (1942). Interference factors in delayed response in monkeys after removal of frontal lobes. Neurophysics 5: 295-308.
63. Manes F, Sahakian BJ, Clark L, Rogers R, Antoun N, Aitken M et al (2002). Decision-making processes following damage to the prefrontal cortex. Brain 125: 624-639.
64. Manji HK, Lenox RH (1999). Protein kinase C signaling in the brain: molecular transduction of mood stabilization in the treatment of manic-depressive illness. Biol Psychiatry 46: 1328-1351.
65. Mao Z-M, Arnsten AFT, Li B-M (1999). Local infusion of alpha-1 adrenergic agonist into the prefrontal cortex impairs spatial working memory performance in monkeys. Biol Psychiatry 46: 1259-1265.
66. McLean A, Dowson J, Toone B, Young S, Bazanis E, Robbins TW et al (2004). Characteristic neurocognitive profile associated with adult attention-deficit/hyperactivity disorder. Psychol Med 34: 681-692.
67. Mehta MA, Goodyer IM, Sahakian BJ (2004). Methylphenidate improves working memory and set-shifting in AD/HD: relationships to baseline memory capacity. J Child Psychol Psychiatry 45: 293-305.
68. Mehta MA, Owen AM, Sahakian BJ, Mavaddat N, Pickard JD, Robbins TW (2000). Methylphenidate enhances working memory by modulating discrete frontal and parietal lobe regions in the human brain. J Neurosci 20: RC651-RC656.
69. Miller EK, Li L, Desimone R (1993). Activity of neurons in anterior inferior temporal cortex during a short-term memory task. J Neurosci 13: 1460-1478.
70. Morita M, Nakahara K, Hayashi T (2004). A rapid presentation event-related functional magnetic resonance imaging study of response inhibition in macaque monkeys. Neurosci Lett 356: 203-206.
71. Muir JL, Everitt BJ, Robbins TW (1996). The cerebral cortex of the rat and visual attentional function: dissociable effects of mediofrontal, cingulate, anterior dorsolateral, and parietal cortex lesions on a five-choice serial reaction time task. Cerebral Cortex 6: 470-481.
72. Muller U, Clark L, Lam ML, Moore RM, Murphy CL, Richmond NK et al (2005). Lack of effects of guanfacine on executive and memory functions in healthy male volunteers. Psychopharmacology 182: 205-213.
73. Muller U, von Cramon DY, Pollmann S (1998). D1- versus D2-receptor modulation of visuospatial working memory in humans. J Neurosci 18: 2720-2728.
74. Park L, Nigg JT, Waldman ID, Nummy KA, Huang-Pollock C, Rappley M et al (2005). Association and linkage of alpha-2A adrenergic receptor gene polymorphisms with childhood ADHD. Mol Psychiatry 10: 572-580.
75. Petrides M (1986). The effect of periarcuate lesions in the monkey on the performance of symmetrically and asymmetrically reinforced visual and auditory go, no-go tasks. J Neurosci 6: 2054-2063.
76. Ramos B, Colgan L, Nou E, Ovadia S, Wilson SR, Arnsten AFT (2005). The beta-1 adrenergic antagonist, betaxolol, improves working memory performance in rats and monkeys. Biol Psychiatry 58: 894-900.
77. Ramos B, Stark D, Verduzco L, Arnsten AFT (2006). Guanfacine improves prefrontal cortical reulation of behavior through inhibition of cAMP/PKA signaling. (in submission).
78. Rapoport JL, Inoff-Germain G (2002). Responses to methylphenidate in attention-deficit/hyperactivity disorder and normal children: update 2002. J Atten Disord 6: S57-S60.
79. Raskind MA, Peskind ER, Kanter ED, Petrie EC, Radant A, Thompson C et al (2003). Prazosin reduces nightmares and other PTSD symptoms in combat veterans: a placebo-controlled study. Am J Psychiatry 160: 371-373.
80. Roman T, Schmitz M, Polanczyk GV, Eizirik M, Rohde LA, Hutz MH (2003). Is the alpha-2A adrenergic receptor gene (ADRA2A) associated with attention-deficit/hyperactivity disorder? Am J Med Genet B Neuropsychiat Genet 120: 116-120.
81. Rubia K, Overmeyer S, Taylor E, Brammer M, Williams SCR, Simmons A et al (1999). Hypofrontality in attention deficit hyperactivity disorder during higher-order motor control: a study with functional MRI. Am J Psychiatry 156: 891-896.
82. Rubia K, Smith AB, Brammer MJ, Taylor E (2003). Right inferior prefrontal cortex mediates response inhibition while mesial prefrontal cortex is responsible for error detection. Neuroimage 20: 351-358.
83. Sawaguchi T (1998). Attenuation of delay-period activity of monkey prefrontal cortical neurons by an alpha-2 adrenergic antagonist during an oculomotor delayed-response task. J Neurophysiol 80: 2200-2205.
84. Schoechlin C, Engel RR (2005). Neuropsychological performance in adult attention-deficit hyperactivity disorder: meta-analysis of empirical data. Arch Clin Neuropsychol 20: 727-744.
85. Segal DS, Kuczenski R (1987). Individual differences in responsiveness to single and repeated amphetamine administration: behavioral characteristics and neurochemical correlates. J Pharmacol Exp Ther 242: 917-926.
86. Segal DS, Kuczenski R (1997a). Repeated binge exposures to amphetamine and methamphetamine: behavioral and neurochemical characterization. J Pharmacol Exp Ther 282: 561-573.
87. Segal DS, Kuczenski R (1997b). An escalating dose 'binge' model of amphetamine psychosis: behavioral and neurochemical characteristics. J Neurosci 17: 2551-2566.
88. Segal DS, Kuczenski R (1999). Escalating dose-binge treatment with methylphenidate: role of serotonin in the emergent behavioral profile. J Pharmacol Exp Ther 291: 19-30.
89. Seidman LJ, Valera EM, Makris N (2005). Structural brain imaging of attention-deficit/hyperactivity disorder. Biol Psychiatry 57: 1263-1272.
90. Sowell ER, Thompson PM, Welcome SE, Henkenius AL, Toga AW, Peterson BS (2003). Cortical abnormalities in children and adolescents with attention-deficit hyperactivity disorder. Lancet 362: 1699-1707.
91. Steere JC, Arnsten AFT (1997). The alpha-2A noradrenergic agonist, guanfacine, improves visual object discrimination reversal performance in rhesus monkeys. Behav Neurosci 111: 1-9.
92. Tanila H, Rama P, Carlson S (1996). The effects of prefrontal intracortical microinjections of an alpha-2 agonist, alpha-2 antagonist and lidocaine on the delayed alternation performance of aged rats. Brain Res Bull 40: 117-119.
93. Thompson-Schill SL, Jonides J, Marshuetz C, Smith EE, D'Esposito M, Kan IP et al (2002). Effects of frontal lobe damage on interference effects in working memory. Cogn Affect Behav Neurosci 2: 109-120.
94. Turner DC, Blackwell AD, Dowson JH, McLean A, Sahakian BJ (2005). Neurocognitive effects of methylphenidate in adult attention-deficit/ hyperactivity disorder. Psychopharmacology 178: 286-295.
95. van Mourik R, Oosterlaan J, Sergeant JA (2005). The Stroop revisited: a meta-analysis of interference control in AD/HD. J Child Psychol Psychiatry 46: 150-165.
96. Van Tol HHM, Bunzow JR, Guan H-C, Sunahara RK, Seeman P, Niznik HB et al (1991). Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 350: 610-614.
97. Vijayraghavan S, Wang M, Birnbaum SG, Bruce CJ, Williams GV, Arnsten AFT (2006). Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged in working memory. Nat Neurosci (in submission).
98. Volkow ND, Fowler JS, Wang GJ, Ding YS, Gatley SJ (2002a). Role of dopamine in the therapeutic and reinforcing effects of methylphenidate in humans: results from imaging studies. Eur Neuropsychopharmacol 12: 557-566.
99. Volkow ND, Wang GJ, Fowler JS, Thanos PP, Logan J, Gatley SJ et al (2002b). Brain DA D2 receptors predict reinforcing effects of stimulants in humans: replication study. Synapse 46: 79-82.
100. Wallis JD, Anderson KC, Miller EK (2001). Single neurons in prefrontal cortex encode abstract rules. Nature 411: 953-956.
101. Wang M, Ramos B, Paspalas C, Duque A, Vijayraghavan S, Brennan A et al (2006). 2A-Adrenoceptor stimulation enhances working memory by closing Ih channels and strengthening functional connectivity of prefrontal cortical microcircuitry (in preparation).
102. Wang M, Tang ZX, Li BM (2004). Enhanced visuomotor associative learning following stimulation of alpha 2A-adrenoceptors in the ventral prefrontal cortex in monkeys. Brain Res 1024: 176-182.
103. Watanabe M (1986). Prefrontal unit activity during delayed conditional go/no-go discrimination in the monkey I. Relation to the stimulus. Brain Res Rev 382: 1-14.
104. Wilkins AJ, Shallice T, McCarthy R (1987). Frontal lesions and sustained attention. Neuropsychologia 25: 359-365.
105. Williams GV, Goldman-Rakic PS (1995). Blockade of dopamine D1 receptors enhances memory fields of prefrontal neurons in primate cerebral cortex. Nature 376: 572-575.
106. Woods DL, Knight RT (1986). Electrophysiological evidence of increased distractability after dorsolateral prefrontal lesions. Neurology 36: 212-216.
107. Yamaguchi S, Knight RT (1990). Gating of somatosensory input by human prefrontal cortex. Brain Res 521: 281-288.
108. Yeo RA, Hill D, Campbell R, Vigil J, Brooks WM (2000). Developmental instability and working memory ability in children: a magnetic resonance spectroscopy investigation. Dev Neuropsychol 17: 143-159.
109. Zahrt J, Taylor JR, Mathew RG, Arnsten AFT (1997). Supranormal stimulation of dopamine D1 receptors in the rodent prefrontal cortex impairs spatial working memory performance. J Neurosci 17: 8528-8535.